PharmaDepth

Company profile

TAKEDA PHARMACEUTICAL CO LTD

NYSE:TAKBiotechnology: Pharmaceutical Preparations

Drug pipeline (119)

AssetStageRevenueTrialsStatus
.ALPHA.1-PROTEINASE INHIBITOR HUMANapproved—6approved
Alogliptin Benzoateapproved—1approved
Amoxicillinapproved—14approved
Amphetamine sulfateapproved—3approved
ANAGRELIDE HYDROCHLORIDEapproved—2approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (1326)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT03808493phase1completed2019-01-302019-03-12TakedaA Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet
NCT02401464phase1completed2015-03-012015-05-01TakedaA Bioequivalence Study of TAK-536 Pediatric Formulation
NCT03437564phase1completed2018-02-162018-04-13TakedaA Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets
NCT00500149phase3completed2007-06-132007-12-05ShireA Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
NCT03878953phase3withdrawn2022-08-312023-05-31ShireA Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism

FDA applications (72)

ApplicationTypeApplicantProducts
BLA 022575BLATakeda Pharmaceuticals U.S.A., Inc.
BLA 101447BLATakeda Pharmaceuticals U.S.A., Inc.
BLA 101448BLATakeda Pharmaceuticals U.S.A., Inc.
BLA 101452BLATakeda Pharmaceuticals U.S.A., Inc.
BLA 103133BLATakeda Pharmaceuticals U.S.A., Inc.